)
Nam-Gu Her, PhD
CEO
Aimed Bio
Dr. Nam-Gu Her is the CEO of AimedBio Inc., a biotech company spun out from Samsung Medical Center that focuses on developing next-generation antibody-based therapeutics, including ADCs and bispecific antibodies. He has led the company from its Series B financing through its successful IPO on KOSDAQ in December 2025.
Before becoming CEO, he served as the first Head of R&D at Aimed Bio, where he led the establishment of the company’s early R&D programs. Prior to joining Aimed Bio, Dr. Her led both the Antibody Discovery Team and the Drug Screening Team at Samsung Medical Center, directing translational oncology research and therapeutic target validation projects.
He has closed multiple global licensing and R&D collaboration deals and secured over 10 government grants as Principal Investigator. Dr. Her has extensive experience in biotech innovation, operations, and business development, and continues to lead Aimed Bio’s global growth and pipeline expansion.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}